Adverse Event reporting information can be found in footer

Request a Meeting

REAL WORLD EVIDENCE (CORE PRACTICE STUDY)1

Thumbnail Image

CLINICAL IMPROVEMENT AND REMISSION RATES

COHORT INFORMATION

DISTRIBUTION AND EXTENT OF UC

TIME TO SYMPTOM RESOLUTION1

PATIENTS ARE HIGHLY SATISFIED WITH CORTIMENT TREATMENT1

FURTHER RESULTS

CORTIMENT® ACHIEVES REMISSION IN FLARING MILD TO MODERATE UC PATIENTS1

 

Thumbnail Image
Thumbnail Image

Alignnone Image 1 x 9mg CORTIMENT® tablet OD for up to 8 weeks2

COHORT INFORMATION3

 

 

Patient Numbers Dose Schedule
59 (16.9%) CORTIMENT® added >14 days after 5-ASA optimisation for current flare
260 (74.5%) CORTIMENT® added ≤14 days after 5-ASA optimisation for current flare or without dose modification
30 (8.6%) CORTIMENT® monotherapy

Alignnone Image 1 x 9mg CORTIMENT® tablet OD for up to 8 weeks2

CORTIMENT® IS EFFECTIVE IN FLARING MILD TO MODERATE UC PATIENTS1

Distribution and extent of UC:

Alignnone Image 1 x 9mg CORTIMENT® tablet OD for up to 8 weeks2

Thumbnail Image
Thumbnail Image

Symptom resolution: Rectal bleeding score of 0 and stool frequency score of 1

Alignnone Image 1 x 9mg CORTIMENT® tablet OD for up to 8 weeks2

Thumbnail Image
Thumbnail Image

Alignnone Image 1 x 9mg CORTIMENT® tablet OD for up to 8 weeks2

CORTIMENT® IS EFFECTIVE IN FLARING MILD TO MODERATE UC PATIENTS1

 

Thumbnail Image

Alignnone Image 1 x 9mg CORTIMENT® tablet OD for up to 8 weeks2

 

 

STUDY SUMMARY

STUDY SUMMARY

Results from a prospective, multi-centre, observational cohort study assessing
the effectiveness of CORTIMENT for mild to moderate active UC

Patient Numbers Dose Schedule
59 (16.9%) CORTIMENT® added >14 days after 5-ASA optimisation for current flare
260 (74.5%) CORTIMENT® added ≤14 days after 5-ASA optimisation for current flare or without dose modification
30 (8.6%) CORTIMENT® monotherapy

BASELINE CHARACTERISTICS 1

  • 349 adult patients (18–86) with mild to moderate UC*
  • Distribution and extent of UC:

 

 

  • CORTIMENT was prescribed within a 5 day time window after study enrolment
  • 35.8% (n=125) of patients had previously received oral steroids, 28.1% (n=98) had
    a history of immunosuppressants and 10.3% (n=36) with biologics

*Intention-to-Treat (IIT) population

SAFETY RESULTS1

24.1% (n=84) of patients reported at least one AE

14.3% (n=50) of patients discontinued CORTIMENT due to AEs

 

17.5% (n=61) of patients reported at least one AE related to the study drug

 

3% (n=9) of patients had worsening of the underlying UC

See the results from the CORE II RCT Study

FIND OUT MORE

  • Danese S, et al. J Crohns Colitis. 2019;13(supplement 1):296–297.
  • Cortiment 9 mg, Prolonged Release Tablets. SmPC.
  • Data on file CSR. Ferring UK Ltd.
  • Danese S, et al. Intestinal Research. 2018;16(4):522–528.
Further Clinical Efficacy
iSTART
Prescribing Cortiment
Resources

Job Code: UK-COR-2200001 - Date of preparation: January 2022

cookiepopup

Our use of cookies

We use cookies (including third party cookies) to collect data while you use this website in order to make it work, keep it secure and comply with regulations. We’d also like your consent to use cookies so we can provide you with tailored content and advertising and analyse how you and other people use the website.

Select “On” to consent to our use of these cookies and continue to the website, or select “Off” to control which types of cookies we use. You can read more about cookies in our Privacy Policy.

Necessary cookies

Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.

Analytics cookies

We’d like to set Google Analytics cookies to help us to improve our website by collecting and reporting information on how you use it. The cookies collect information in away that does not directly identify anyone. For more information on how these cookies work, please see our Privacy Policy.